CombiGene AB (publ) (COMBI.ST)
SEK 2.7
(-0.74%)
SEK 2.7
(-0.74%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.66 Million SEK | -564.55% |
| 2022 | -5.36 Million SEK | -125.6% |
| 2021 | 20.96 Million SEK | 168.12% |
| 2020 | -30.77 Million SEK | -72.51% |
| 2019 | -17.83 Million SEK | -35.7% |
| 2018 | -13.14 Million SEK | -46.75% |
| 2017 | -8.95 Million SEK | -3.37% |
| 2016 | -8.66 Million SEK | -33.97% |
| 2015 | -6.46 Million SEK | -573.5% |
| 2014 | -960.5 Thousand SEK | -3393.37% |
| 2013 | -27.49 Thousand SEK | -132.85% |
| 2012 | -11.8 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -7.56 Million SEK | 46.69% |
| 2024 Q1 | -14.19 Million SEK | -123.18% |
| 2023 Q1 | -14.61 Million SEK | -22.4% |
| 2023 Q4 | -6.36 Million SEK | 24.31% |
| 2023 Q3 | -8.4 Million SEK | -33.68% |
| 2023 FY | -35.66 Million SEK | -564.55% |
| 2023 Q2 | -6.28 Million SEK | 57.0% |
| 2022 Q3 | 3.95 Million SEK | -12.47% |
| 2022 FY | -5.36 Million SEK | -125.6% |
| 2022 Q1 | -2.68 Million SEK | -104.67% |
| 2022 Q2 | 4.51 Million SEK | 268.26% |
| 2022 Q4 | -11.94 Million SEK | -402.09% |
| 2021 Q2 | -15.4 Million SEK | -41.88% |
| 2021 Q1 | -10.85 Million SEK | 0.99% |
| 2021 Q3 | -10.22 Million SEK | 33.61% |
| 2021 Q4 | 57.44 Million SEK | 661.84% |
| 2021 FY | 20.96 Million SEK | 168.12% |
| 2020 Q3 | -6.44 Million SEK | -46.87% |
| 2020 Q2 | -4.38 Million SEK | 42.12% |
| 2020 Q1 | -7.58 Million SEK | 14.59% |
| 2020 FY | -30.77 Million SEK | -72.51% |
| 2020 Q4 | -10.96 Million SEK | -70.1% |
| 2019 Q3 | -3.44 Million SEK | -22.25% |
| 2019 Q4 | -8.87 Million SEK | -158.09% |
| 2019 FY | -17.83 Million SEK | -35.7% |
| 2019 Q1 | -2.47 Million SEK | 21.78% |
| 2019 Q2 | -2.81 Million SEK | -13.88% |
| 2018 Q1 | -1.99 Million SEK | 39.3% |
| 2018 FY | -13.14 Million SEK | -46.75% |
| 2018 Q4 | -3.15 Million SEK | 45.79% |
| 2018 Q3 | -5.82 Million SEK | -169.94% |
| 2018 Q2 | -2.15 Million SEK | -8.0% |
| 2017 Q1 | 249 Thousand SEK | 109.74% |
| 2017 FY | -8.95 Million SEK | -3.37% |
| 2017 Q4 | -3.29 Million SEK | -16.99% |
| 2017 Q3 | -2.81 Million SEK | 9.22% |
| 2017 Q2 | -3.1 Million SEK | -1345.38% |
| 2016 Q1 | -1.39 Million SEK | 40.95% |
| 2016 FY | -8.66 Million SEK | -33.97% |
| 2016 Q4 | -2.55 Million SEK | -1.89% |
| 2016 Q3 | -2.5 Million SEK | -6.95% |
| 2016 Q2 | -2.34 Million SEK | -67.93% |
| 2015 Q3 | -1.32 Million SEK | 22.75% |
| 2015 Q1 | -1.05 Million SEK | -17.53% |
| 2015 FY | -6.46 Million SEK | -573.5% |
| 2015 Q4 | -2.36 Million SEK | -78.16% |
| 2015 Q2 | -1.71 Million SEK | -62.78% |
| 2014 Q3 | -46 Thousand SEK | 0.0% |
| 2014 Q4 | -898.5 Thousand SEK | -1853.27% |
| 2014 Q2 | - SEK | 100.0% |
| 2014 Q1 | -16 Thousand SEK | 0.0% |
| 2014 FY | -960.5 Thousand SEK | -3393.37% |
| 2013 FY | -27.49 Thousand SEK | -132.85% |
| 2012 FY | -11.8 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 85.653% |
| Ziccum AB (publ) | -21.41 Million SEK | -66.567% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -99.281% |
| BioArctic AB (publ) | 229.24 Million SEK | 115.557% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -8042.786% |
| Mendus AB (publ) | -101.61 Million SEK | 64.903% |
| Genovis AB (publ.) | 61.5 Million SEK | 157.993% |
| Intervacc AB (publ) | -102.85 Million SEK | 65.324% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -115.853% |
| Active Biotech AB (publ) | -45.8 Million SEK | 22.128% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 393.084% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 37.232% |
| Aptahem AB (publ) | -11.11 Million SEK | -220.938% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 88.53% |
| Kancera AB (publ) | -64.88 Million SEK | 45.036% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 71.02% |
| Fluicell AB (publ) | -26.55 Million SEK | -34.313% |
| Saniona AB (publ) | -95.81 Million SEK | 62.775% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -194.075% |
| Biovica International AB (publ) | -124.82 Million SEK | 71.427% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 15.531% |
| AcouSort AB (publ) | -17.08 Million SEK | -108.704% |
| Xintela AB (publ) | -54.08 Million SEK | 34.054% |
| Abliva AB (publ) | -95.5 Million SEK | 62.658% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 89.09% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 762.187% |
| OncoZenge AB (publ) | -15.9 Million SEK | -124.282% |
| Amniotics AB (publ) | -30.87 Million SEK | -15.534% |
| 2cureX AB (publ) | -32.51 Million SEK | -9.679% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -178.028% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 92.35% |
| Camurus AB (publ) | 431.44 Million SEK | 108.267% |
| Corline Biomedical AB | -1.8 Million SEK | -1871.554% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 79.945% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 3.792% |
| I-Tech AB | 20.2 Million SEK | 276.535% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 95.712% |
| Cyxone AB (publ) | -22.98 Million SEK | -55.141% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 60.979% |
| Biosergen AB | -27.03 Million SEK | -31.913% |
| Cantargia AB (publ) | -280.02 Million SEK | 87.264% |
| NextCell Pharma AB | -41.95 Million SEK | 15.001% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 80.149% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -117.499% |
| Nanologica AB (publ) | -75.15 Million SEK | 52.545% |
| SynAct Pharma AB | -215.81 Million SEK | 83.474% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 19.042% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -50.252% |
| LIDDS AB (publ) | -40.2 Million SEK | 11.293% |
| Lipum AB (publ) | -37.17 Million SEK | 4.069% |
| BioInvent International AB (publ) | -330.3 Million SEK | 89.202% |
| Alzinova AB (publ) | -16.48 Million SEK | -116.416% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 85.683% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -259.168% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 68.528% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -69.102% |
| Simris Alg AB (publ) | -37.3 Million SEK | 4.395% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 76.513% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 90.812% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 67.366% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -205.407% |